Different types of HT aim to suppress testosterone-induced tumor growth through mechanisms including reducing androgen production by the testes (e.g., orchiectomy, luteinizing hormone-releasing hormone (LHRH) or gonadotropin-releasing hormone (GnRH) agonists), blocking androgen production throughout the body (e.g., CYP17 inhibitors), and/or blocking the actions of androgen on the body (also known as antiandrogens, androgen receptor blockers, or antagonists) (American Cancer Society, 2022). Here, GNRH1 is linked to neoplasm.